Labcorp Holdings Inc
LH251.810USD
-2.860-1.12%
Fechamento 01/09, 16:00（ET）Cotações atrasadas em 15 min
20.90BValor de mercado
24.56P/L TTM
Mais detalhes de Labcorp Holdings Inc Empresa
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The Company provides insights and accelerates to improve health and improve lives through its unparalleled diagnostics and drug development capabilities. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
Informações de Labcorp Holdings Inc
Código da empresaLH
Nome da EmpresaLabcorp Holdings Inc
Data de listagemApr 24, 1991
CEOSchechter (Adam H)
Número de funcionários70000
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 24
Endereço358 S Main St
CidadeBURLINGTON
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal27215
Telefone13362291127
Sitehttps://www.labcorp.com/
Código da empresaLH
Data de listagemApr 24, 1991
CEOSchechter (Adam H)
Executivos da empresa Labcorp Holdings Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Adam H. Schechter
Mr. Adam H. Schechter
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
87.57K
-5745.00%
Dr. Brian J. Caveney, M.D., J.D.
Dr. Brian J. Caveney, M.D., J.D.
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
30.07K
-2000.00%
Mr. Lance V. Berberian
Mr. Lance V. Berberian
Executive Vice President - Special Advisor, Strategy
Executive Vice President - Special Advisor, Strategy
22.53K
+1972.00%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Independent Director
Independent Director
12.89K
--
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Lead Independent Director
Lead Independent Director
12.84K
--
Ms. Kerrii B. Anderson, CPA
Ms. Kerrii B. Anderson, CPA
Independent Director
Independent Director
8.67K
-4000.00%
Ms. Amy B. Summy
Ms. Amy B. Summy
Executive Vice President, Chief Marketing Officer
Executive Vice President, Chief Marketing Officer
5.30K
+757.00%
Mr. Mark S. Schroeder
Mr. Mark S. Schroeder
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
4.96K
--
Mr. Akinbolade Oyegunwa
Mr. Akinbolade Oyegunwa
Executive Vice President and Chief Information and Technology Officer
Executive Vice President and Chief Information and Technology Officer
3.73K
+263.00%
Ms. Megan D. Bailey
Ms. Megan D. Bailey
Executive Vice President and President - Central Laboratories and International
Executive Vice President and President - Central Laboratories and International
3.59K
+191.00%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Adam H. Schechter
Mr. Adam H. Schechter
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
87.57K
-5745.00%
Dr. Brian J. Caveney, M.D., J.D.
Dr. Brian J. Caveney, M.D., J.D.
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
30.07K
-2000.00%
Mr. Lance V. Berberian
Mr. Lance V. Berberian
Executive Vice President - Special Advisor, Strategy
Executive Vice President - Special Advisor, Strategy
22.53K
+1972.00%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Independent Director
Independent Director
12.89K
--
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Lead Independent Director
Lead Independent Director
12.84K
--
Ms. Kerrii B. Anderson, CPA
Ms. Kerrii B. Anderson, CPA
Independent Director
Independent Director
8.67K
-4000.00%
Detalhamento da receita
Moeda: USDAtualizado em: qua, 12 de mar
Moeda: USDAtualizado em: qua, 12 de mar
FY2021
FY2020
FY2019
Os dados relevantes ainda não foram divulgados pela empresa.
Por RegiãoUSD
Nome
Receita
Proporção
Northern America
13.09B
81.22%
Europe
2.05B
12.72%
Other Countries
976.40M
6.06%
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: dom, 16 de nov
Atualizado em: dom, 16 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
11.79%
BlackRock Institutional Trust Company, N.A.
5.30%
State Street Investment Management (US)
4.62%
Victory Capital Management Inc.
3.18%
Geode Capital Management, L.L.C.
2.56%
Outro
72.54%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
11.79%
BlackRock Institutional Trust Company, N.A.
5.30%
State Street Investment Management (US)
4.62%
Victory Capital Management Inc.
3.18%
Geode Capital Management, L.L.C.
2.56%
Outro
72.54%
Tipos de investidores
Investidores
Proporção
Investment Advisor
50.39%
Investment Advisor/Hedge Fund
38.82%
Research Firm
2.40%
Pension Fund
1.76%
Hedge Fund
1.61%
Bank and Trust
1.56%
Sovereign Wealth Fund
1.25%
Individual Investor
0.36%
Family Office
0.26%
Outro
1.59%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
1803
80.86M
97.54%
-4.56M
2025Q3
1802
83.09M
100.23%
+765.81K
2025Q2
1825
81.46M
98.03%
-5.42M
2025Q1
1872
81.69M
97.58%
-5.17M
2024Q4
1872
81.10M
96.90%
-5.32M
2024Q3
1856
80.09M
95.55%
-6.82M
2024Q2
1876
81.29M
96.43%
-7.49M
2024Q1
1904
82.39M
97.73%
-8.65M
2023Q4
1947
83.11M
99.02%
-9.76M
2023Q3
1930
84.34M
99.29%
-7.18M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
9.78M
11.79%
-66.55K
-0.68%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
4.39M
5.3%
-10.58K
-0.24%
Sep 30, 2025
State Street Investment Management (US)
3.83M
4.62%
-31.13K
-0.81%
Sep 30, 2025
Victory Capital Management Inc.
2.64M
3.18%
+440.22K
+20.04%
Sep 30, 2025
Geode Capital Management, L.L.C.
2.12M
2.56%
+9.78K
+0.46%
Sep 30, 2025
Wellington Management Company, LLP
2.11M
2.54%
+289.03K
+15.91%
Sep 30, 2025
Allspring Global Investments, LLC
2.00M
2.41%
-4.51K
-0.23%
Sep 30, 2025
Select Equity Group, L.P.
1.84M
2.22%
-295.76K
-13.87%
Sep 30, 2025
Diamond Hill Capital Management Inc.
1.64M
1.98%
-181.26K
-9.94%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
1.25M
1.5%
-41.66K
-3.23%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares U.S. Healthcare Providers ETF
3.32%
Knowledge Leaders Developed World ETF
2.73%
Thrivent Small-Mid Cap ESG ETF
2.26%
State Street SPDR S&P Health Care Services ETF
1.9%
Schwab Ariel Opportunities ETF
1.62%
Brandes US Value ETF
1.56%
Invesco S&P 500 Equal Weight Health Care ETF
1.52%
Madison Covered Call ETF
1.49%
Nuveen ESG Mid-Cap Value ETF
1.4%
Franklin Genomic Advancements ETF
1.25%
Ver Mais
iShares U.S. Healthcare Providers ETF
Proporção3.32%
Knowledge Leaders Developed World ETF
Proporção2.73%
Thrivent Small-Mid Cap ESG ETF
Proporção2.26%
State Street SPDR S&P Health Care Services ETF
Proporção1.9%
Schwab Ariel Opportunities ETF
Proporção1.62%
Brandes US Value ETF
Proporção1.56%
Invesco S&P 500 Equal Weight Health Care ETF
Proporção1.52%
Madison Covered Call ETF
Proporção1.49%
Nuveen ESG Mid-Cap Value ETF
Proporção1.4%
Franklin Genomic Advancements ETF
Proporção1.25%
Dividendo
Um total de
692.30M
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Oct 08, 2025
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Dec 11, 2025 going ex on Nov 26, 2025
Nov 26, 2025
Dec 11, 2025
Nov 26, 2025
Jul 10, 2025
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Sep 11, 2025 going ex on Aug 28, 2025
Aug 28, 2025
Sep 11, 2025
Aug 28, 2025
Apr 10, 2025
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Jun 11, 2025 going ex on May 29, 2025
May 29, 2025
Jun 11, 2025
May 29, 2025
Jan 09, 2025
LH.NB Final Cash Dividend of gross USD 0.72 paid on Mar 12, 2025 going ex on Feb 27, 2025
Feb 27, 2025
Mar 12, 2025
Feb 27, 2025
Oct 10, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Dec 13, 2024 going ex on Nov 26, 2024
Nov 26, 2024
Dec 13, 2024
Nov 26, 2024
Jul 25, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Sep 13, 2024 going ex on Aug 29, 2024
Aug 29, 2024
Sep 13, 2024
Aug 29, 2024
Apr 11, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Jun 12, 2024 going ex on May 24, 2024
May 28, 2024
Jun 12, 2024
May 24, 2024
Jan 12, 2024
LH.NB Final Cash Dividend of gross USD 0.72 paid on Mar 13, 2024 going ex on Feb 26, 2024
Feb 27, 2024
Mar 13, 2024
Feb 26, 2024
Oct 12, 2023
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Dec 12, 2023 going ex on Nov 07, 2023
Nov 08, 2023
Dec 12, 2023
Nov 07, 2023
Jul 13, 2023
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Sep 08, 2023 going ex on Aug 07, 2023
Aug 08, 2023
Sep 08, 2023
Aug 07, 2023
Ver Mais
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
Perguntas frequentes
Quem são os cinco principais acionistas de Labcorp Holdings Inc?
Os cinco principais acionistas de Labcorp Holdings Inc são:
The Vanguard Group, Inc. detém 9.78M Ações, representando 11.79% do total de Ações.
BlackRock Institutional Trust Company, N.A. detém 4.39M Ações, representando 5.30% do total de Ações.
State Street Investment Management (US) detém 3.83M Ações, representando 4.62% do total de Ações.
Victory Capital Management Inc. detém 2.64M Ações, representando 3.18% do total de Ações.
Geode Capital Management, L.L.C. detém 2.12M Ações, representando 2.56% do total de Ações.
The Vanguard Group, Inc. detém 9.78M Ações, representando 11.79% do total de Ações.
BlackRock Institutional Trust Company, N.A. detém 4.39M Ações, representando 5.30% do total de Ações.
State Street Investment Management (US) detém 3.83M Ações, representando 4.62% do total de Ações.
Victory Capital Management Inc. detém 2.64M Ações, representando 3.18% do total de Ações.
Geode Capital Management, L.L.C. detém 2.12M Ações, representando 2.56% do total de Ações.
Quais são os três principais tipos de acionistas de Labcorp Holdings Inc?
Os três principais tipos de acionistas da Labcorp Holdings Inc são:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Quantas instituições possuem ações da Labcorp Holdings Inc (LH)?
Em 2025Q4, 1803 instituições possuíam ações da Labcorp Holdings Inc, com valor de mercado aproximado de 80.86M, representando 97.54% do total de ações. Em comparação com 2025Q3, a participação institucional aumentou em -2.70%.
Qual é a maior fonte de receita da Labcorp Holdings Inc?
Em FY2021, o segmento de negócios -- gerou a maior receita para Labcorp Holdings Inc, totalizando -- e representando --% da receita total.
